Soleno Therapeutics, Inc. (SLNO): Price and Financial Metrics
SLNO Price/Volume Stats
| Current price | $54.83 | 52-week high | $59.75 |
| Prev. close | $51.79 | 52-week low | $26.38 |
| Day low | $51.78 | Volume | 673,300 |
| Day high | $55.51 | Avg. volume | 469,075 |
| 50-day MA | $52.97 | Dividend yield | N/A |
| 200-day MA | $46.91 | Market Cap | 2.36B |
SLNO Stock Price Chart Interactive Chart >
Soleno Therapeutics, Inc. (SLNO) Company Bio
Soleno Therapeutics, Inc. focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. The companys lead candidate, diazoxide choline controlled-release (DCCR), a once-daily oral tablet for the treatment of Prader-Willi Syndrome (PWS), is entering into Phase II/III clinical development. It also markets medical devices, including the CoSense End-Tidal Carbon Monoxide (ETCO) monitor, which measures ETCO and is used by hospitals to detect hemolysis in newborns; and NeoPip T-piece resuscitator and related consumables, which deliver consistent pre-set inspiratory pressure and positive end-expiratory pressures, as well as temperature probes, scales, surgical tables, and patient surfaces. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. May 2017. Soleno Therapeutics, Inc. was founded in 1999 and is based in Redwood City, California.
SLNO Price Returns
| 1-mo | 2.22% |
| 3-mo | 21.17% |
| 6-mo | 33.21% |
| 1-year | 95.82% |
| 3-year | 440.25% |
| 5-year | 135.83% |
| YTD | 36.22% |
| 2023 | 1,932.83% |
| 2022 | -67.80% |
| 2021 | -78.76% |
| 2020 | -34.35% |
| 2019 | 71.93% |
Loading social stream, please wait...